Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Breast Neoplasms 19Lung Neoplasms 11Stomach Neoplasms 9Colorectal Neoplasms 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Ovarian Neoplasms 7Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms, Male 4Thyroid Neoplasms 3Sarcoma 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Melanoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Vulvar Neoplasms 2Vipoma 2Vaginal Neoplasms 2Uterine Neoplasms 2

Interventions

pembrolizumab 3osimertinib 2Trastuzumab 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2ulixertinib 1tucatinib 1trastuzumab biosimilar HLX02 1trametinib 1seribantumab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1cobimetinib 1cemiplimab 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Uncertainty 1Sunitinib 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Neoplasms × Trastuzumab × Thoracic × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡